Fate Therapeutics, Inc.
MINIMAL VOLUME REPROGRAMMING OF MONONUCLEAR CELLS
Last updated:
Abstract:
The invention provides compositions and methods for reprogramming minimal volumes of mononuclear cells. In particular aspects, the invention provides methods and compositions for reprogramming minimal volumes of umbilical cord blood obtained from cord blood segments from cryopreserved cord blood segments.
Status:
Application
Type:
Utility
Filling date:
23 Feb 2021
Issue date:
1 Jul 2021